BioCentury | May 21, 2009
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Reticulon 4 receptor (RTN4R; NgR) Studies in mice suggest that a soluble peptide fragment of NgR (sNgR)...
BioCentury | May 7, 2009
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Integrin a9 (ITGA9) Studies in cell culture and in rats suggest that upregulating ITGA9 could help treat...
BioCentury | Jan 29, 2007
Tools & Techniques

Little vascular plasters

Trigen Holdings AG sees its PR-15 as a bandage that moves through the bloodstream patching up collagen exposed in damaged vascular walls. The company thinks the platelet adhesion inhibitor may have less severe bleeding side...
BioCentury | Jan 29, 2007
Company News

Millennium, Trigen Holdings AG deal

Trigen received exclusive worldwide rights to develop and commercialize MLNM's IP covering glycoprotein VI ( GPVI ), a platelet collagen receptor involved in thrombosis. Trigen expects to complete Phase I testing of PR-15 to treat acute...
BioCentury | May 8, 2006
Finance

Europe’s Iceberg 2006

Europe’s biotech sector has reached a stage of maturity where companies need to raise substantial amounts of money to support product development. In recent years, VCs have stepped up to the plate, with top-tier privates...
BioCentury | Oct 17, 2005
Finance

Ebb & Flow

Germany's Jerini has been tipped as a potential European IPO for more than a year, but the company has always maintained that it would go when the climate was right. The company has decided that...
BioCentury | Oct 12, 2005
Financial News

Trigen raises EUR 26.5 million

Trigen (London, U.K.) raised EUR 26.5 million ($32.1 million) in its first round of funding since merging with ProCorde in April. The round was led by Wellington Partners; HealthCap; and 3i. Other investors included SR...
BioCentury | Sep 19, 2005
Clinical News

ProCord: Phase I data

In an Israeli Phase I trial in 8 patients, ProCord was well tolerated with no evidence of neurological deterioration. Patients were enrolled in the study within 14 days of their injury and had a complete...
BioCentury | Jul 25, 2005
Strategy

European takeouts

European takeouts Completed Acquirer Country Acquired Country Value Jan Paradigm Therapeutics U.K. Amedis U.K. Undisclosed Jan Sinclair Pharma (LSE:SPH) U.K. Euroderm RDC Italy E6M ($7.2M) in cash & stock Jan Solvay (Euronext:SOLB) Belgium NeoPharma Sweden...
BioCentury | Jul 25, 2005
Strategy

Choosing to survive

Building sustainable biotech businesses when investors are playing hard to get is forcing European CEOs to think about making some hard choices. For some that means surrendering their independence, for others it means thinking about...
Items per page:
1 - 10 of 20
BioCentury | May 21, 2009
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Reticulon 4 receptor (RTN4R; NgR) Studies in mice suggest that a soluble peptide fragment of NgR (sNgR)...
BioCentury | May 7, 2009
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Integrin a9 (ITGA9) Studies in cell culture and in rats suggest that upregulating ITGA9 could help treat...
BioCentury | Jan 29, 2007
Tools & Techniques

Little vascular plasters

Trigen Holdings AG sees its PR-15 as a bandage that moves through the bloodstream patching up collagen exposed in damaged vascular walls. The company thinks the platelet adhesion inhibitor may have less severe bleeding side...
BioCentury | Jan 29, 2007
Company News

Millennium, Trigen Holdings AG deal

Trigen received exclusive worldwide rights to develop and commercialize MLNM's IP covering glycoprotein VI ( GPVI ), a platelet collagen receptor involved in thrombosis. Trigen expects to complete Phase I testing of PR-15 to treat acute...
BioCentury | May 8, 2006
Finance

Europe’s Iceberg 2006

Europe’s biotech sector has reached a stage of maturity where companies need to raise substantial amounts of money to support product development. In recent years, VCs have stepped up to the plate, with top-tier privates...
BioCentury | Oct 17, 2005
Finance

Ebb & Flow

Germany's Jerini has been tipped as a potential European IPO for more than a year, but the company has always maintained that it would go when the climate was right. The company has decided that...
BioCentury | Oct 12, 2005
Financial News

Trigen raises EUR 26.5 million

Trigen (London, U.K.) raised EUR 26.5 million ($32.1 million) in its first round of funding since merging with ProCorde in April. The round was led by Wellington Partners; HealthCap; and 3i. Other investors included SR...
BioCentury | Sep 19, 2005
Clinical News

ProCord: Phase I data

In an Israeli Phase I trial in 8 patients, ProCord was well tolerated with no evidence of neurological deterioration. Patients were enrolled in the study within 14 days of their injury and had a complete...
BioCentury | Jul 25, 2005
Strategy

European takeouts

European takeouts Completed Acquirer Country Acquired Country Value Jan Paradigm Therapeutics U.K. Amedis U.K. Undisclosed Jan Sinclair Pharma (LSE:SPH) U.K. Euroderm RDC Italy E6M ($7.2M) in cash & stock Jan Solvay (Euronext:SOLB) Belgium NeoPharma Sweden...
BioCentury | Jul 25, 2005
Strategy

Choosing to survive

Building sustainable biotech businesses when investors are playing hard to get is forcing European CEOs to think about making some hard choices. For some that means surrendering their independence, for others it means thinking about...
Items per page:
1 - 10 of 20